Company profile
Exicure
Exicure is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases
- Industry
- Biotechnology Research
- Employees
- 5
- Headquarters
- Chicago, Illinois
- Founded
- 2011
- LinkedIn followers
- 4,148
- Office locations
- 1
Exicure company summary
Exicure is a company in the Biotechnology Research industry, headquartered in Chicago, Illinois, founded in 2011. On LinkedIn the company has around 5 employees and 4,148 followers.
What technology does Exicure use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Our team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, IL, Exicure conducts its discovery and development efforts in-house with a dedicated 30,000 sq. ft. facility, including rapid and automated high throughput nucleic acid synthesis and screening. Our platform for therapeutic nucleic acids demonstrates high potency, broad uptake, and prolonged efficacy in both in vitro and in vivo neurological models. The basis of our discovery approach harnesses our expertise in oligonucleotide chemistry to validated targets where we can screen thousands of oligonucleotides efficiently and validate top candidates in the appropriate cell and live animal models. Exicure's lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A (Nav1.7). Exicure has also identified several promising candidates across a series of CNS conditions with high unmet need including Huntington disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis.
Where is Exicure located?
Exicure lists 1 location.
Compare companies similar to Exicure
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Exicure exicuretx.com | Biotechnology Research | 5 | 2011 | Chicago, Illinois |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Exicure
What does Exicure do?
Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Our team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, IL, Exicure conducts its discovery and development efforts in-house with a dedicated 30,000 sq. ft. facility, including rapid and automated high throughput nucleic acid synthesis and screening. Our platform for therapeutic nucleic acids demonstrates high potency, broad uptake, and prolonged efficacy in both in vitro and in vivo neurological models. The basis of our discovery approach harnesses our expertise in oligonucleotide chemistry to validated targets where we can screen thousands of oligonucleotides efficiently and validate top candidates in the appropriate cell and live animal models. Exicure's lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A (Nav1.7). Exicure has also identified several promising candidates across a series of CNS conditions with high unmet need including Huntington disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis.
How many employees does Exicure have?
Exicure has around 5 employees on LinkedIn.
Where is Exicure headquartered?
Exicure is headquartered in Chicago, Illinois.
When was Exicure founded?
Exicure was founded in 2011.
Build a lead list from companies like Exicure
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.